Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955493 | 0.94 | GABRP (0.47) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL18452361 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL18453785 | 0.88 | KDM4E (0.52) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL9671501 | 0.88 | KDM4E (0.52) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL2953375 | 0.86 | MAPK14 (0.43) | PTPN2PTPN1PTPN6PTPN11DRD2 | |
| SCHEMBL20929141 | 0.81 | PTPN2 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19PTPN2 | |
| SCHEMBL11553778 | 0.81 | MAPK14 (0.47) | DRD2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18506683 | 0.81 | FFAR1 (0.53) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL139332 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL1310397 | 0.81 | MAPT (0.54) | KDM4EALDH1A1CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10343982-B2 | Compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-3049506-B1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| WO-2015043713-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-04-02 | — | — | WO | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2046746-A2 | CHEMICAL COMPOUNDS | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MTX1, NEFM, MTX2 | KDM4E 4677/4885ALDH1A1 2642/4885CYP1A2 936/4885 |
| US-10343982-B2 | Compounds and mesogenic media | MTX1, NEFM, MTX2 | KDM4E 4677/4885ALDH1A1 2642/4885CYP1A2 936/4885 |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | KDM4E 1586/4885ALDH1A1 2402/4885CYP1A2 2411/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | KDM4E 3445/4885ALDH1A1 1132/4885CYP1A2 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.